-
Ratio Therapeutics Partners with Novartis on SSTR2 Radiotherapeutic for Cancer
•
US-based Ratio Therapeutics Inc. has entered into a global exclusive licensing and cooperation agreement with Swiss pharmaceutical giant Novartis AG (NYSE: NVS) to develop a Somatostatin Receptor 2 (SSTR2) radiotherapeutic candidate for cancer treatment. Details of the AgreementRatio will apply its radioligand therapy discovery and development expertise, along with its…
-
MGI Tech Partners with OncoDNA to Enhance Precision Oncology Solutions
•
MGI Tech Co., Ltd., (SHA: 688114) a China-based leader in gene sequencing, announced a strategic collaboration with Belgium’s OncoDNA, a company specializing in precision medicine for cancer and genetic diseases. The partnership integrates the OncoDEEP Kit’s comprehensive workflow—including sequencing, secondary analysis, and final interpretation of next-generation sequencing (NGS) data through…
-
Amoy Diagnostics’ APACE Receives Japanese Approval as Companion Diagnostic for MET-Inhibiting Therapies
•
Amoy Diagnostics Co., Ltd (AmoyDx, SHE: 300685), a Chinese diagnostics company, has announced that it has received two new indication approvals in Japan for its APACE (also known as PCR-11 gene product), a multi-target rapid screening product designed for lung cancer detection. The product is now approved as a companion…
-
Jiangsu Vcare Pharma Partners with Geneseeq Technology to Develop Companion Diagnostic for NTRK Inhibitor
•
Jiangsu Vcare PharmaTech Co., Ltd, a biopharmaceutical company based in China, has entered into a partnership with Sino-Canadian firm Geneseeq Technology Inc. The collaboration aims to jointly develop and commercialize a companion diagnostic (CDx) reagent for Vcare’s NTRK inhibitor VC004. Financial details of the agreement were not disclosed. Preliminary clinical…
-
CStone Pharmaceuticals Submits New Drug Application for Gavreto in China, Eyes Local Manufacturing
•
CStone Pharmaceuticals (HKG: 2616), a leading biopharmaceutical company based in China, has submitted a market approval filing to the National Medical Products Administration (NMPA) for Gavreto (pralsetinib), an oral, once-daily, highly selective RET inhibitor. The company plans to manufacture the drug locally, marking a strategic shift from overseas supply. Gavreto…
-
Bristol Myers Squibb’s Krazati Trial Yields Positive Phase III Results in NSCLC
•
Last week, Bristol Myers Squibb (BMS; NYSE: BMY) unveiled preliminary results from a Phase III confirmatory trial for its KRAS inhibitor Krazati (adagrasib) in patients with pretreated locally advanced or metastatic non-small cell lung cancer (NSCLC) carrying a KRASG12C mutation. This encouraging data reinforces BMS’s strategic 2023 acquisition of original…
-
Jiangsu Hengrui Receives NMPA Approval for Phase Ib/II Study of HRS2398 in Advanced Solid Tumors
•
Jiangsu Hengrui Medicine Co., Ltd (SHA: 600276), a leading pharmaceutical company based in China, has announced that it has received approval from the National Medical Products Administration (NMPA) to initiate an open, multi-center Phase Ib/II study. The study will assess the drug candidate HRS2398 in combination with HRS-1167 or adebrelimab…
-
CSPC Pharmaceutical Gets NMPA Greenlight for SYH2039 Clinical Study in Advanced Malignant Tumors
•
CSPC Pharmaceutical Group Ltd (HKG: 1093), a leading pharmaceutical company based in China, has received approval from the National Medical Products Administration (NMPA) to proceed with a clinical study for its Category 1 chemical drug candidate, SYH2039, which targets advanced malignant tumors. SYH2039 is a potent inhibitor of methionine adenosine…
-
Matridx Bio Secures Series C+ Funding to Advance Infectious Pathogens Diagnostics
•
Hangzhou Matridx Biotechnology Co., Ltd, a specialist in molecular diagnostics for infectious pathogens based in China, has reportedly secured “hundreds of millions” of renminbi in a Series C+ financing round. The investment was led by a state-owned fund in Yuhang, Zhejiang province, and other undisclosed participants. The funds raised will…
-
Merck KGaA’s Tepmetko Launches in China, Expanding Access to MET Inhibitor for Lung Cancer Patients
•
Merck KGaA (NYSE: MRK), a leading German science and technology company, has announced the commercial launch of its targeted lung cancer therapy, Tepmetko (tepotinib), in China. This marks a significant milestone as multiple hospitals across the country have begun writing the first prescriptions for this MET inhibitor. Tepmetko, which has…
-
Ping An Good Doctor Partners with Vcanbio to Pioneer Cell Health Management Services in China
•
Ping An Healthcare and Technology Co., Ltd (HKG: 1833), commonly referred to as PingAn Good Doctor, has entered into a strategic partnership with Vcanbio Cell & Gene Engineering Corp., Ltd (SHA: 600645), another Chinese firm. The collaboration aims to combine the business acumen and technical prowess of both companies to…
-
Roche Commences Phase II Trial of Repare Therapeutics’ ATR Inhibitor, Camonsertib, in Solid Tumors
•
Swiss pharmaceutical giant Roche (SWX: ROG) has reached a significant milestone this week with the dosing of the first patient in an open-label Phase II trial using its Canadian partner Repare Therapeutics’ (NASDAQ: RPTX) ATR inhibitor, camonsertib. The trial aims to evaluate the safety and efficacy of various targeted therapies…
-
Glorious Med and Illumina Join Forces for Advanced Urinary Tract Infection Detection
•
Hangzhou-based Glorious Med, a premier company specializing in gene detection for urinary system tumors, has entered into a partnership with US genomics giant Illumina (NSDQ: ILMN). The collaboration aims to advance the precise diagnosis of urinary tract pathogens and drug resistance genes through the use of Illumina’s Urinary Pathogen/Drug Resistance…
-
BMS’ Augtyro Receives EMA Review for Advanced Lung Cancer and Solid Tumors Treatments
•
The European Medicines Agency (EMA) has accepted for review a filing submitted by Bristol Myers Squibb (BMS; NYSE: BMY) for its orphan drug, Augtyro (repotrectinib), which targets ROS1-positive locally advanced or metastatic non-small cell lung cancer (NSCLC) and NTRK-positive locally advanced or metastatic solid tumors. The next-generation tyrosine kinase inhibitor…
-
Bayer Partners with ClearNote Health to Explore Prostate Cancer Treatment Response
•
German multinational pharmaceutical company Bayer (ETR: BAYN) has partnered with U.S. diagnostics firm ClearNote Health to delve into the study of treatment response and resistance in metastatic hormone-sensitive prostate cancer. The collaborative project will leverage ClearNote’s epigenomic platform, which employs machine learning algorithms to analyze patient blood samples, monitor DNA-based…
-
Bosscome Science & Technology Secures Series A Funding for Precision Medical Navigation Systems
•
Bosscome Science & Technology, a Chongqing-based developer of integrated optical and magnetic navigation systems, has reportedly secured “tens of millions” of renminbi in a Series A financing round led by Zhongxi Life Investment Partnership and Rayfund Investment. The funds raised will be allocated towards market promotion of its submillimeter level…
-
Bayer Partners with Hurdle to Launch Saliva-Based Age Tests in Global E-Commerce
•
Bayer (ETR: BAYN), the German multinational, has announced a strategic collaboration to globally distribute Hurdle’s saliva-based Chronomics biological age tests through electronic channels. Based in the UK, Hurdle specializes in diagnostics, and its at-home biomarker tests utilize epigenetic markers to measure biological age, positioning them as precision health solutions aimed…
-
Janssen Submits Indication Extension Application to FDA for Rybrevant in NSCLC Treatment
•
The Janssen unit of Johnson & Johnson (J&J; NYSE: JNJ) has filed an indication extension application with the US Food and Drug Administration (FDA) for its bispecific antibody Rybrevant (amivantamab) in combination with chemotherapy. The treatment is intended for patients with locally advanced or metastatic non-small cell lung cancer (NSCLC)…
-
BMS’s Augtyro Receives FDA Approval for ROS1-Positive NSCLC
•
The US Food and Drug Administration (FDA) has granted Bristol Myers Squibb (BMS, NYSE: BMY) registration approval for its next-generation tyrosine kinase inhibitor (TKI) Augtyro (repotrectinib) for the treatment of locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC) in adults. This decision follows a priority review of Phase…
-
Aiming Med Partners with Becton, Dickinson and Co. to Advance Tumor Precision Medicine
•
Aiming Med, a leading provider of tumor precision medicine solutions based in Hangzhou, has announced a strategic partnership with Becton, Dickinson and Co. (BD) during the 6th China International Import Expo (CIIE) in Shanghai this week. This collaboration aims to enhance the application of advanced tumor organoid and single-cell multi-omics…
-
Janssen’s Nipocalimab Shows Promising Results in Phase II Rheumatoid Arthritis Trial
•
The Janssen unit of Johnson & Johnson (J&J; NYSE: JNJ) has announced the results of a Phase II trial for nipocalimab, a potential best-in-class anti-neonatal Fc (FcRn) biologic, in patients with moderate-to-severe active rheumatoid arthritis (RA) who have anti-citrullinated protein antibodies (ACPAs) or rheumatoid factor (RF) and are unresponsive to…
-
Bayer and Shanghai Pharmaceuticals Launch Co.Lab to Incubate Life Sciences Innovation in China
•
Bayer, the Germany-headquartered multinational pharmaceutical and life sciences company (ETR: BAYN), has entered into a partnership with Shanghai Pharmaceuticals, a leading China-based pharmaceutical distribution giant (SPH; HKG: 2607; SHA: 601607), to co-construct a new life sciences incubator named Co.Lab. This collaboration is designed to foster cutting-edge innovation in cell and…
-
Sansure Biotech Partners with Shaanxi Lifegen to Boost Molecular Diagnostics
•
China-based molecular diagnostics specialist Sansure Biotech Inc. (SHA: 688289) has formed a strategic partnership with fellow Chinese firm Shaanxi Lifegen Co. Ltd. The collaboration aims to deepen efforts in platform construction, sequencing, and full product development, although financial details of the partnership were not disclosed. Scope of the PartnershipThe partnership…
-
Roche’s Alecensa Shows Unprecedented 76% Improvement in Disease-Free Survival in NSCLC Trial
•
Roche (SWX: ROG) subsidiary Genentech has revealed preliminary but promising results from a Phase III trial for Alecensa (alectinib) in patients with early-stage resected ALK-positive non-small cell lung cancer (NSCLC). The trial demonstrated that the ALK inhibitor significantly improved disease-free survival (DFS) by an unprecedented 76% compared to chemotherapy, meeting…
-
Eurofarma Invests in Abcuro as Part of $100 Million Disruptive Startups and Biotech Initiative
•
Brazil-based multinational company (MNC) Eurofarma has announced an investment in US immunotherapy developer Abcuro as part of a broader program to invest up to USD 100 million in potentially disruptive startups and biotechnology companies in the discovery and development phase. This 5-year project aims to support up to 25 companies…
